Dr. Matthew Taylor is a medical oncologist and translational researcher with more than 15 years of experience leading early-phase cancer immunotherapy clinical trials. His work at the Providence Cancer Institute has focused on understanding why the immune system fails to sustain its attack on tumors.

That research led to the discovery and development of M3T01, Gamma’s first-in-class monoclonal antibody designed to block FasL and protect the body’s immune defense. Dr. Taylor continues to bridge clinical insight and laboratory innovation, advancing therapies that help the immune system fight the battle against cancer.